See more : coinIX GmbH & Co. KGaA (XCX.DU) Income Statement Analysis – Financial Results
Complete financial analysis of PURE Bioscience, Inc. (PURE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PURE Bioscience, Inc., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
- Atresmedia Corporación de Medios de Comunicación, S.A. (ATVDY) Income Statement Analysis – Financial Results
- No Borders, Inc. (NBDR) Income Statement Analysis – Financial Results
- AEON Credit Service (M) Berhad (5139.KL) Income Statement Analysis – Financial Results
- Harfang Exploration Inc. (HAR.V) Income Statement Analysis – Financial Results
- Wasko S.A. (WAS.WA) Income Statement Analysis – Financial Results
PURE Bioscience, Inc. (PURE)
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.96M | 1.88M | 1.85M | 3.93M | 6.92M | 1.91M | 1.77M | 1.83M | 1.29M | 729.00K | 550.00K | 820.00K | 812.00K | 464.18K | 1.44M | 728.26K | 1.49M | 336.39K | 200.43K | 155.81K | 263.50K | 2.59M | 3.21M | 2.41M | 1.66M | 3.40M | 1.70M | 1.00M | 800.00K |
Cost of Revenue | 811.00K | 906.00K | 853.00K | 1.85M | 2.90M | 728.00K | 763.00K | 760.00K | 441.00K | 285.00K | 344.00K | 565.00K | 264.00K | 131.39K | 465.09K | 238.17K | 463.60K | 221.11K | 105.72K | 51.59K | 130.90K | 1.53M | 1.60M | 1.36M | 885.25K | 1.30M | 900.00K | 600.00K | 600.00K |
Gross Profit | 1.15M | 971.00K | 1.00M | 2.08M | 4.02M | 1.18M | 1.01M | 1.07M | 848.00K | 444.00K | 206.00K | 255.00K | 548.00K | 332.79K | 971.04K | 490.10K | 1.02M | 115.28K | 94.71K | 104.21K | 132.60K | 1.06M | 1.61M | 1.05M | 776.21K | 2.10M | 800.00K | 400.00K | 200.00K |
Gross Profit Ratio | 58.69% | 51.73% | 53.97% | 52.84% | 58.13% | 61.86% | 56.99% | 58.49% | 65.79% | 60.91% | 37.45% | 31.10% | 67.49% | 71.69% | 67.61% | 67.30% | 68.83% | 34.27% | 47.25% | 66.89% | 50.32% | 40.76% | 50.15% | 43.45% | 46.72% | 61.76% | 47.06% | 40.00% | 25.00% |
Research & Development | 302.00K | 297.00K | 319.00K | 339.00K | 322.00K | 354.00K | 459.00K | 779.00K | 927.00K | 790.00K | 1.03M | 1.33M | 1.86M | 2.18M | 1.93M | 1.47M | 1.65M | 1.22M | 1.19M | 1.36M | 1.13M | 981.49K | 780.51K | 292.96K | 114.76K | 200.00K | 200.00K | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 4.05M | 0.00 | 6.42M | 7.59M | 6.30M | 6.98M | 7.29M | 8.32M | 5.72M | 7.44M | 6.52M | 4.93M | 5.46M | 5.14M | 3.74M | 2.61M | 1.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 927.94K | 694.07K | 805.63K | 899.15K | 570.16K | 427.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 3.98M | 4.30M | 4.11M | 4.05M | 3.70M | 6.42M | 7.59M | 6.30M | 6.98M | 7.29M | 8.32M | 5.72M | 7.44M | 6.52M | 5.86M | 6.16M | 5.95M | 3.74M | 2.61M | 1.76M | 1.63M | 3.28M | 2.77M | 2.57M | 2.31M | 1.50M | 2.40M | 1.90M | 700.00K |
Other Expenses | 0.00 | -4.00K | 0.00 | -4.00K | 5.00K | 1.00K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 109.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 277.83K | 0.00 | 212.17K | 100.00K | 100.00K | 100.00K | 0.00 |
Operating Expenses | 4.28M | 4.60M | 4.43M | 4.39M | 4.02M | 6.77M | 8.05M | 7.08M | 7.91M | 8.08M | 9.35M | 7.04M | 9.30M | 8.70M | 7.79M | 7.62M | 7.70M | 4.96M | 3.81M | 3.12M | 2.76M | 4.27M | 3.83M | 2.87M | 2.64M | 1.80M | 2.70M | 2.00M | 700.00K |
Cost & Expenses | 5.09M | 5.51M | 5.28M | 6.24M | 6.91M | 7.50M | 8.82M | 7.84M | 8.35M | 8.37M | 9.70M | 7.61M | 9.57M | 8.83M | 8.25M | 7.86M | 8.17M | 5.18M | 3.91M | 3.17M | 2.89M | 5.80M | 5.43M | 4.23M | 3.52M | 3.10M | 3.60M | 2.60M | 1.30M |
Interest Income | 0.00 | 14.00K | 6.00K | 4.00K | 5.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 7.77K | 33.31K | 18.72K | 30.79K | 150.88K | 0.00 | 0.00 | 191.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 155.00K | 14.00K | 6.00K | 4.00K | 5.00K | 6.00K | 8.00K | 5.00K | 10.00K | 8.00K | 10.00K | 0.00 | 145.00K | -232.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 315.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 148.00K | 117.00K | 213.00K | 172.00K | 192.00K | 241.00K | 285.00K | 276.00K | 219.00K | 185.00K | 2.14M | 601.00K | 377.00K | 460.60K | 442.05K | 396.47K | 403.38K | 219.59K | 310.90K | 305.53K | 348.72K | 314.08K | 734.63K | 290.44K | 252.37K | 100.00K | 100.00K | -100.00K | 0.00 |
EBITDA | -3.05M | -3.83M | -3.27M | -2.14M | 201.00K | -6.31M | -7.15M | -5.99M | -14.14M | -7.43M | -8.90M | -6.48M | -8.36M | -7.91M | -6.29M | -6.74M | -6.28M | -4.62M | -3.46M | -2.74M | -2.35M | -3.25M | -1.49M | -1.32M | -1.61M | 400.00K | -1.80M | -1.70M | -500.00K |
EBITDA Ratio | -155.22% | -187.27% | -173.34% | -54.57% | 2.91% | -280.09% | -379.48% | -299.40% | 36.15% | -1,022.63% | -1,274.18% | -754.51% | -1,031.65% | -1,703.28% | -443.97% | -925.21% | -421.99% | -1,373.77% | -1,697.21% | -1,736.55% | -864.41% | -111.82% | -46.32% | -63.40% | -96.71% | 11.76% | -105.88% | -170.00% | -62.50% |
Operating Income | -3.13M | -3.94M | -3.43M | -2.31M | 9.00K | -5.59M | -7.04M | -6.01M | 247.00K | -7.64M | -9.15M | -6.79M | -8.75M | -8.37M | -6.82M | -7.13M | -6.68M | -4.84M | -3.71M | -3.01M | -2.63M | -3.21M | -2.22M | -1.82M | -1.86M | 300.00K | -1.90M | -1.60M | -500.00K |
Operating Income Ratio | -159.50% | -210.07% | -184.84% | -58.85% | 0.13% | -292.77% | -396.96% | -328.13% | 19.16% | -1,048.01% | -1,663.27% | -827.80% | -1,078.08% | -1,802.51% | -474.75% | -979.65% | -449.11% | -1,439.05% | -1,852.32% | -1,932.65% | -996.75% | -123.95% | -69.24% | -75.45% | -111.90% | 8.82% | -111.76% | -160.00% | -62.50% |
Total Other Income/Expenses | -219.00K | -18.00K | 233.00K | -8.00K | 0.00 | -965.00K | -400.00K | -255.00K | -7.31M | 13.00K | 852.00K | -332.00K | -136.00K | 17.77K | 60.35K | 69.53K | 142.44K | 188.37K | 32.12K | -638.00 | -194.43K | 402.98K | -280.23K | -167.58K | 34.67K | 0.00 | 0.00 | 200.00K | 0.00 |
Income Before Tax | -3.35M | -3.96M | -3.49M | -2.32M | 4.00K | -6.55M | -7.44M | -6.26M | -14.37M | -7.63M | -11.05M | -7.67M | -8.75M | -8.36M | -6.76M | -7.06M | -6.54M | -4.65M | -3.68M | -3.01M | -2.70M | -3.19M | -2.50M | -1.78M | -1.82M | 0.00 | 0.00 | -1.40M | 0.00 |
Income Before Tax Ratio | -170.66% | -211.03% | -188.40% | -59.05% | 0.06% | -343.32% | -419.50% | -342.05% | -1,114.90% | -1,046.23% | -2,009.09% | -935.49% | -1,077.09% | -1,800.35% | -470.55% | -970.11% | -439.53% | -1,383.05% | -1,836.30% | -1,933.06% | -1,024.56% | -123.06% | -77.98% | -73.89% | -109.81% | 0.00% | 0.00% | -140.00% | 0.00% |
Income Tax Expense | 0.00 | 10.00K | 6.00K | -68.56K | 10.00K | 7.00K | 33.00K | 255.00K | 7.31M | -13.00K | 1.90M | 883.00K | 136.00K | -17.77K | 2.52K | 2.40K | 2.40K | 2.40K | 132.39K | -1.16M | -318.77K | 74.35K | 224.88K | 1.60K | 800.00 | 0.00 | 0.00 | -200.00K | -100.00K |
Net Income | -3.35M | -3.96M | -3.50M | -2.32M | -6.00K | -6.56M | -7.48M | -6.52M | -21.69M | -7.61M | -12.95M | -8.55M | -8.88M | -8.34M | -6.76M | -7.07M | -6.54M | -4.65M | -3.81M | -1.85M | -2.38M | -3.26M | -2.73M | -1.78M | -1.83M | 300.00K | -1.90M | -1.20M | -400.00K |
Net Income Ratio | -170.66% | -211.03% | -188.72% | -59.05% | -0.09% | -343.69% | -421.36% | -355.98% | -1,682.31% | -1,044.44% | -2,354.91% | -1,043.17% | -1,093.84% | -1,796.53% | -470.73% | -970.43% | -439.70% | -1,383.77% | -1,902.35% | -1,185.53% | -903.58% | -125.93% | -84.99% | -73.96% | -109.86% | 8.82% | -111.76% | -120.00% | -50.00% |
EPS | -0.03 | -0.04 | -0.04 | -0.03 | 0.00 | -0.09 | -0.11 | -0.10 | -0.38 | -0.19 | -0.51 | -0.79 | -1.58 | -1.79 | -1.57 | -1.85 | -1.90 | -1.52 | -1.49 | -0.92 | -1.55 | -2.86 | -2.85 | -2.24 | -3.01 | 0.47 | -3.92 | -2.88 | -1.12 |
EPS Diluted | -0.03 | -0.04 | -0.04 | -0.03 | 0.00 | -0.09 | -0.11 | -0.10 | -0.38 | -0.19 | -0.51 | -0.79 | -1.58 | -1.79 | -1.57 | -1.85 | -1.90 | -1.52 | -1.49 | -0.92 | -1.55 | -2.86 | -2.85 | -2.24 | -1.81 | 0.31 | -3.92 | -2.88 | -1.12 |
Weighted Avg Shares Out | 111.86M | 111.40M | 88.84M | 87.17M | 82.21M | 72.88M | 67.28M | 63.49M | 56.83M | 39.75M | 25.61M | 10.84M | 5.62M | 4.67M | 4.32M | 3.82M | 3.44M | 3.06M | 2.56M | 2.01M | 1.53M | 1.14M | 955.04K | 795.64K | 605.61K | 637.50K | 484.69K | 416.67K | 357.14K |
Weighted Avg Shares Out (Dil) | 111.86M | 111.40M | 88.84M | 87.17M | 84.61M | 72.88M | 67.28M | 63.49M | 56.83M | 39.75M | 25.61M | 10.84M | 5.62M | 4.67M | 4.32M | 3.82M | 3.44M | 3.06M | 2.56M | 2.01M | 1.53M | 1.14M | 955.04K | 795.64K | 1.01M | 637.50K | 484.69K | 416.67K | 357.14K |
PURE Bioscience Announces Distribution Agreement with AFCO, a Zep Company
PURE Bioscience Announces Distribution Agreement with Quip Laboratories
PURE Bioscience Reports Fiscal 2024 Financial Results
PURE Bioscience Announces Distribution Agreement with Madison Chemical Co., Inc.
PURE Bioscience Announces Distribution Agreement with Zee Company
PURE Bioscience Announces Distribution Agreement with ChemStation
PURE Bioscience to Unveil its Newest Food Safety Solutions at the Annual International Association for Food Protection Meeting
PURE Bioscience Announces an International Supply and License Agreement with AgroVet Alliance
PURE Bioscience Reports Fiscal Third Quarter 2024 Financial Results
PURE Bioscience Appoints Darin Zehr to Board of Directors
Source: https://incomestatements.info
Category: Stock Reports